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http://dx.doi.org/10.1016/j.ccell.2014.11.008SUMMARYIn PTEN-mutated tumors, we show that PI3Ka activity is suppressed and PI3K signaling is driven by PI3Kb. A
selective inhibitor of PI3Kb inhibits the Akt/mTORpathway in these tumors but not in those driven by receptor
tyrosine kinases. However, inhibition of PI3Kb only transiently inhibits Akt/mTOR signaling because it re-
lieves feedback inhibition of IGF1R and other receptors and thus causes activation of PI3Ka and a rebound
in downstream signaling. This rebound is suppressed and tumor growth inhibition enhanced with combined
inhibition of PI3Ka and PI3Kb. In PTEN-deficient models of prostate cancer, this effective inhibition of PI3K
causes marked activation of androgen receptor activity. Combined inhibition of both PI3K isoforms and
androgen receptor results in major tumor regressions.INTRODUCTION
The PI3K/Akt/mTOR signaling pathway is aberrantly activated
by mutation in many cancers (Cancer Genome Atlas, 2012).
Dysregulation of PI3K signaling in these tumors results in
increased pathway output and is accompanied by exagger-
ated physiologic feedback inhibition of receptor tyrosine ki-
nase (RTK) signaling, which normally serves to limit the extent
and duration of activation of the pathway (Chandarlapaty,
2012). In model systems, PI3K signaling has been shown to
be necessary for the maintenance of tumors in which it is acti-
vated (She et al., 2008). However, the therapeutic benefit of in-
hibitors of PI3K, Akt, and mTOR has been modest (Fruman and
Rommel, 2014). For instance, loss of function of PTEN due to
mutations occurs in more than 40% of metastatic prostateSignificance
PI3K inhibition by PI3Kb inhibitors is transient because of relief
is required for maximal pathway inhibition and antitumor activit
inhibition of each isoform with these drugs, their combined ad
PI3K inhibitors and be easier to combine with other therapie
has been ineffective because it causes activation of androgen
hibitors combined with a potent androgen receptor inhibitor s
ways and results in near complete suppression of androgen r
Ccancers (Taylor et al., 2010), yet TORC1 inhibitors, such as ra-
pamycin analogs, are inactive in this disease (Armstrong et al.,
2013).
The modest efficacy of these inhibitors has been attributed to
several factors, including the coexistence of other mutations and
relief of feedback inhibition of physiologic signaling in tumors
treated with pathway inhibitors (Chandarlapaty et al., 2011; Car-
racedo et al., 2008; Halilovic et al., 2010; Serra et al., 2011; Ihle
et al., 2009). Many PI3K inhibitors and ‘‘dual-specificity inhibi-
tors’’ that inhibit both mTOR and PI3K are not selective, and
off-target toxicity may limit pathway inhibition and efficacy
(Brachmann et al., 2012; Toledo et al., 2011). Furthermore,
PI3K subserves many key physiologic functions, and its inhibi-
tion may be limited by hyperglycemia and other on-target toxic-
ities (Martini et al., 2013).of feedback so that combined inhibition of PI3Ka and PI3Kb
y. Because of their greater selectivity and the ability to titrate
ministration may cause less toxicity than less specific pan-
s. Prostate cancer treatment with PI3K signaling inhibitors
receptor. Triple therapy with PI3Ka and PI3Kb selective in-
uppresses the reciprocal feedback activation of both path-
eceptor-dependent prostate tumors in vivo.
ancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc. 109
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PI3Kb Isoform Inhibitors in PTEN-Mutated TumorsRecently, isoform selective PI3K inhibitors have been devel-
oped and shown to have limited toxicity even at high doses (Juric
et al., 2012). Several groups have found that in tumorswith PI3Ka
mutation or those in which PI3K signaling is driven by activated
RTKs, PI3Ka is the dominant isoform, whereas in tumors with
PTEN mutations, PI3Kb is dominant (Knight et al., 2006; Ni
et al., 2012; Wee et al., 2008). Consistent with these data,
PI3Kb, but not PI3Ka, was required for the development of pros-
tate tumors in the anterior prostate (AP) of a Pten-deficient
genetically engineered mouse (GEM) model (Jia et al., 2008,
Jia et al., 2013).
These findings suggest that selective inhibitors of PI3Kb will
effectively inhibit PI3K signaling in tumors in which PTEN is inac-
tivated and will therefore have significant antitumor activity. In
this study, we tested this hypothesis.
RESULTS
PI3Kb Inhibitors Transiently Inhibit PI3K Signaling in
PTEN-Mutated Models
AZD8186 (Figure S1A available online), an ATP-competitive in-
hibitor of PI3Kb and PI3Kd, was used in these studies. In the Ac-
tivX assay for inhibition of kinases, 250 nMAZD8186 appreciably
inhibited only PI3Kb (98% inhibition) and PI3Kd (92% inhibition)
and did not inhibit other kinases, including mTOR (S.S. and
S.C., unpublished data). In an in vitro kinase assay using the cat-
alytic domains of the different PI3K isoforms as substrates (see
Supplemental Experimental Procedures), the IC50 of AZD8186
for PI3Kb was 4 nM; PI3Kd, 12 nM; PI3Ka, 35 nM; and PI3Kg,
675 nM.
We determined the concentrations at which AZD8186 inhibits
PI3K signaling and cell growth in BT-474, a HER2-dependent
breast cancer cell line in which signaling is driven by PI3Ka (Tor-
bett et al., 2008), and in LNCaP, a PTEN-mutated prostate carci-
noma cell line. In BT-474, up to 250 nM AZD8186 had no effect
on Akt/mTOR signaling, but 500 nM had some effect (Fig-
ure S1B). Two hundred fifty nM AZD8186 also had little effect
on BT-474 growth (Figure S1C), so we concluded that it is a se-
lective inhibitor of PI3Kb at this concentration.
Akt phosphorylation was significantly inhibited in the PTEN-
mutated LNCaP exposed to 25 nM AZD8186 for 2 hr (Fig-
ure S1D). Thus, in these cells, AZD8186 inhibits PI3K signaling
at concentrations more than 10-fold below those that inhibit
PI3Ka or mTOR. LNCaP proliferation was correspondingly sen-
sitive to AZD8186 (IC50 100 ± 92 nM) (Figure S1E). Two hundred
fifty nM AZD8186, a concentration that afforded selective inhibi-
tion of PI3Kb, were used in subsequent studies.
When LNCaP or the PTEN-mutated triple negative breast can-
cer (TNBC) cell line BT-549 were exposed to 250 nM AZD8186,
PI3K signalingwas rapidly inhibited but subsequently rebounded
(Figures 1A and 1B). Akt phosphorylation was maximally in-
hibited after 30 min of AZD8186 treatment of BT-549 and after
2 hr of treatment of LNCaP (Figures 1A–1C). Dephosphorylation
of the Akt substrate PRAS40 occurs with the same kinetics (Fig-
ures 1A–1C). Rebound in the phosphorylation of Akt T308 and
PRAS40 occurred in both cell lines, 2 hr after treatment of
BT-549 and 4 hr afterward in LNCaP (Figures 1A–1C). Rebound
of Akt S473 phosphorylation occurred more slowly after 6 hr of
drug treatment (Figures 1A–1C). After 24 hr of treatment of110 Cancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc.LNCaP cells, phosphorylation of Akt T308 rises to 85% of base-
line, P-Akt (S473) to 35%, and P-PRAS40 to 50% of baseline
(Figures 1A and 1C). In BT-549 cells, the phosphorylation of
Akt T308 rises to 70%, P-Akt S473 to 50% and P-PRAS40 to
30% of baseline (Figures 1B and 1C).
To determine the generality of the phenomenon, the effects of
AZD8186 were assessed in a panel of 11 cell lines with PTEN
inactivation. PI3K signaling was rapidly inhibited by the drug
and then rebounded significantly hours later in all of the cell lines
(Table S1). AZD8186 caused significant inhibition of cell growth
in 7 of the 11 cell lines, with IC50s for growth inhibition in the
range of concentrations that selectively inhibit PI3Kb. In cell lines
with WT PTEN, PI3Kb inhibition did not inhibit PI3K signaling or
cell proliferation (Table S1). An unrelated PI3Kb inhibitor GSK-
2636771 is selective against p110b at 1 mM and also caused
rapid inhibition of PI3K signaling in LNCaP that rebounded after
4 to 8 hr (Figures S1F–S1H).
Rebound of Akt Signaling after PI3Kb Inhibition Is PI3Ka
Dependent
Reactivation of Akt signaling after PI3Kb inhibition is not likely to
be due to decreasing intracellular drug concentrations since
readdition of 250 nM AZD8186 to cells after the initial exposure
to drug did not inhibit phosphorylation of Akt or PRAS40 (Figures
1D and 1E). We asked whether rebound is due to induction of
other class 1 PI3K isoforms. Expression of p110g or p110d pro-
tein was not detected in LNCaP or BT-549 cells treated with the
PI3Kb-inhibitor (AZD8186, 250 nM), and expression of p110a,
p110b, and of p85 was unchanged (Figures S1I and S1J).
The selective PI3Ka inhibitor BYL719 (Fritsch et al., 2014) had
no effect on the phosphorylation of Akt or Akt substrates in
LNCaP or BT-549 cells (Figures 2A and S2A). However, in both
cell lines, combining PI3Kb (AZD8186) and PI3Ka (BYL719) in-
hibitors markedly reduced the rebound in phosphorylation of
Akt and its substrates that occurred with AZD8186 alone (Fig-
ures 2A and S2A). Similar findings were obtained in the PTEN-
mutated TNBC cell line HCC70 and the prostate cancer cell
line PC3 (Figures S2B and S2C). Thus, in these cells, PI3Ka
does not drive PI3K signaling, but is responsible for the rebound
in PI3K signaling that occurs after PI3Kb inhibition.
These results suggest that PI3Ka activity is low in these cells
and induced after PI3Kb inhibition. To test this possibility,
in vitro PI3K assays were performed on PI3Ka immunoprecipi-
tated from lysates of LNCaP cells exposed to AZD8186 (Fig-
ure 2B). PI3Ka activity, as measured by the accumulation of
P32-labeled, phosphatidylinositol 3-phosphate, was induced
3.9-fold 4 hr after PI3Kb inhibition, reaching a peak (5-fold induc-
tion) at 6–8 hr. Expression of the PI3Ka protein was unchanged
(Figure 2B). We conclude that after inhibition of PI3Kb in PTEN-
mutated tumor cells, induction of PI3Ka kinase activity occurs
and is in part responsible for the rebound in Akt/mTOR signaling.
The durable inhibition of PI3K signaling achieved by com-
bining inhibitors of PI3Kb and PI3Ka has biologic conse-
quences. PI3Kb inhibition causes significant slowing of LNCaP
growth in culture, but proliferation persists and cell number
begins to increase 3–4 days after drug addition (Figure 2C).
PI3Ka inhibition has little effect, but the combination completely
suppresses growth (Figure 2C) and induces PARP and Caspase
3 cleavage (Figure 2A) and apoptosis (Figure 2D). Similar effects
Figure 1. PI3Kb Inhibition in PTEN Mutant Models Leads to a Transient Inhibition of the Akt Pathway
(A and B) LNCaP (A) and BT-549 (B) cells were treated with 250 nM AZD8186 as indicated, and the effect on the downstream signaling was analyzed.
(C) The fold change in P-Akt (T308), P-Akt (S473), and P-PRAS40 levels following AZD8186 treatment was determined by densitometric analysis of the bands in
(A) and (B), respectively.
(D and E) LNCaP (D) and BT-549 (E) cells were treated with 250 nM AZD8186 for the indicated times. Lysates were immunoblotted with indicated antibodies (left
panels). After 4 (BT-549 cells) or 6 (LNCaP cells) hr of AZD8186 treatment, AZD8186 was readded to the cells (right) for the indicated times, and lysates were
immunoblotted with the indicated antibodies.
See also Figure S1 and Table S1.
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PI3Kb Isoform Inhibitors in PTEN-Mutated Tumorswere noted in BT-549, HCC70, and PC3 cells treated with the
combination (Figures S2D–S2G).
BAY806946, a PI3K inhibitor that more potently inhibits PI3Ka
than PI3Kb (Glauer et al., 2013), had similar effects as BYL719
in LNCaP— no effect when given alone but significantly
enhanced inhibition of signaling and suppression of growth
when combined with the PI3Kb inhibitor (Figures S2H and S2I).
Thus, inhibition of PI3Ka suppresses the rebound in PI3K
signaling in tumor cells exposed to PI3Kb inhibitors, and this is
associated with enhanced inhibition of cell growth and induction
of apoptosis.
Reactivation of PI3Ka Is IGF1R Dependent
Activation of the PI3K pathway causes feedback inhibition of
RTK signaling via Akt- and mTOR-dependent mechanisms
(Chandarlapaty et al., 2011; O’Reilly et al., 2006; Rodrik-Outmez-
guine et al., 2011). We hypothesized that PI3Kb inhibitors induce
PI3Ka kinase activity by relieving this feedback. Antibody arrays
were used to assess the effect of PI3Kb inhibition on the phos-Cphorylation of 49 RTKs. In LNCaP cells, phosphorylation of
EGFR and HER2 was induced 24 hr after PI3Kb inhibition (Fig-
ure S3A); however, only induction of Y1068 EGFR phosphoryla-
tionwas confirmed by immunoblotting (Figures 3A andS3B), and
the EGFR inhibitor gefitinib (2 mM) prevented induction of EGFR
Y1068 phosphorylation without affecting Akt rebound or inhibi-
tion of cell growth (Figures S3C–S3E).
Previous work showed that inhibition of Akt/mTOR signaling
reactivates the expression and/or activation of multiple RTKs
that regulate the pathway, including IGF1R, insulin receptor
(IR), and HER kinases (Chandarlapaty et al., 2011; Rodrik-Out-
mezguine et al., 2011). Treatment of LNCaP or BT-549 cells
with the PI3Kb inhibitor caused induction of the expression of
HER3 and IGF1R (Figures 3A, S3F, and S3G), but had no effect
on the expression of IR (Figure 3A; S.S. and N.R., unpublished
data). Increased phosphorylation of HER3, IR, or IGF1R was
not detected.
IR, IGF1R, andHER3 are key physiologic activators of the PI3K
pathway. Induction of HER3 is unlikely to play a dominant role inancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc. 111
Figure 2. Reactivation of Akt Signaling following PI3Kb Inhibition Is PI3Ka Dependent
(A) LNCaP cells were treated with AZD8186 (250 nM), BYL719 (2.5 mM), or the combination. Cells were collected at indicated times, and the effect on Akt signaling
and apoptotic markers was analyzed by immunoblotting.
(B) LNCaP cells were treated with AZD8186 for various times. PI3Ka was immunoprecipitated from cell lysate, and PI3K activity assay was performed. The
product, PI3P, was resolved by thin-layer chromatography and detected by autoradiography. A lane with a purified PI3Ka was used as a positive control, and a
lane with IgG was used as a negative control for the assay (left). Whole-cell lysates and immunoprecipitates were blotted with anti-PI3Ka (left). The change in
PI3Ka activity was determined by densitometric analysis of the bands (right).
(C) Cell growth of LNCaP cells treated as indicated was monitored with cell counter. The data represent mean ± SD of triplicate samples.
(D) Apoptotic cell death of LNCaP cells treated as indicated for 48 hr was quantified by Annexin V staining. The data represent mean ± SD of duplicate samples.
See also Figure S2.
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S3C, S3D, S3H, and S3I) nor lapatinib (S.S., unpublished data)
affected Akt rebound or cell growth in LNCaP or BT-549 treated
with AZD8186.112 Cancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc.Activation of Akt/mTOR causes the feedback inhibition of
IGF1R and IR signaling by inhibiting the expression and activa-
tion of both receptors and the expression of the IGF1R/IR sub-
strate (IRS) proteins, IRS1 and IRS2 (Haruta et al., 2000; Simpson
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PI3Kb Isoform Inhibitors in PTEN-Mutated Tumorset al., 2001; Chandarlapaty et al., 2011; O’Reilly et al., 2006).
ELISA assays showed that the expression level of IGF1R rises
significantly from 1,594 to 3,155 pg/ml after 8 hr of PI3Kb inhibi-
tion and is induced 3-fold by 24 hr (Figure S3J). Induction of
IGF1R expression was accompanied by a small increase in its
phosphorylation as assessed by ELISA analysis—1.3-fold induc-
tion after 4 hr of AZD8186 treatment, reaching 1.5-fold induction
after 24 hr (Figure 3B).
The increase in expression of IGF1R is accompanied by
increased expression of the IRS1 protein in LNCaP (1.5-fold after
1 hr and 2.8-fold in 6 hr) and BT-549 cells (1.9-fold induction after
4 hr) (Figures 3C and S3K). In both models, mTOR activation is
dependent on PI3Kb, as demonstrated by the sensitivity of
S6K phosphorylation to AZD8186 (Figures 3C and S3K). Acti-
vated S6K phosphorylates serine sites of IRS1 (S312 and/or
S636/639) that causes the degradation of IRS1 (Haruta et al.,
2000; Um et al., 2004). Increased IRS1 expression in cells treated
with AZD8186 was associated with decreased phosphorylation
of IRS1 S636/639 and increased phosphorylation at Y612, a
site that plays a role in the ability of IRS1 to activate PI3K (Espo-
sito et al., 2001) (Figures 3C and S3K). These data suggest that
inhibition of PI3Kb relieves feedback inhibition of IGF and insulin
signaling by increasing IGF1R and IRS1 expression and thus
causing reactivation of PI3Ka.
To test this hypothesis, we used OSI-906, a dual inhibitor of
the IGF1R and IR kinases (IC50 0.035 mM for IGF1R, 0.075 mM
for IR, and IC50s greater than 10 mM against a panel of 45 other
kinases) (Mulvihill et al., 2009). Combined treatment of LNCaP or
BT-549 with OSI-906 (2 mM) and AZD8186 (250 nM) significantly
diminished and delayed the rebound in Akt signaling observed
with AZD8186 alone (Figures 3D and S3L). OSI-906 enhanced
the growth inhibition caused by AZD8186 almost to the same de-
gree as the PI3Ka inhibitor did (Figures S3M and S3N). OSI-906
alone had slight effects on Akt signaling in LNCaP cells (Fig-
ure 3D). In BT-549, OSI-906 alone induced PRAS40 and
FOXO1/3 phosphorylation and had no effect on Akt or GSK3b
phosphorylation (Figure S3L). Moreover, whereas the IGF1R/IR
inhibitor alone did not induce apoptosis in LNCaP and BT-549
cells, combining AZD8186 and OSI-906 caused a marked in-
crease in apoptosis compared with AZD8186 alone (Figures 3E
and S2G).
These data suggest that relief of feedback inhibition of IRS1
and IGF1R expression plays amajor role in causing the observed
reactivation of PI3Ka signaling. This conclusion is supported by a
knockdown experiment: siRNA-mediated depletion of IRS1 in
LNCaP cells reduced the rebound of Akt phosphorylation in
LNCaP cells exposed to the PI3Kb inhibitor, whereas a scram-
bled siRNA control had no effect (Figure S3O).
Our findings suggest that in PTEN-mutated tumors PI3Kb acti-
vation causes feedback inhibition of IGF1R signaling. If this is the
case, the signaling response to IGF should be blunted unless the
feedback is relieved. To determine whether this is so, we as-
sessed IGF1 induction of PI3K signaling in LNCaP at various
times after PI3Kb inhibition with AZD8186 (Figure 3F). In control
LNCaP cells, IGF1 stimulation for 10 min did not stimulate the
pathway (time 0). After treatment of the cells with AZD8186 for
1 or 2 hr, PI3K signaling was inhibited, but IGF1 stimulation did
not cause phosphorylation of Akt, its substrates, or S6K. After
3 hr of treatment, IGF1 clearly induced phosphorylation of AktCS473, GSK3b, PRAS40, and S6K (Figure 3F). IGF1R expression
and induction of IGF1R phosphorylation were unchanged at that
time, and a rebound in PI3K signaling had not occurred in cells
untreated with IGF1 (Figure 3F). These data are consistent with
enhanced transduction of the IGF1R signal 3 hr after PI3Kb inhi-
bition (Figure 3F). Induction continued to increase up to 7 hr after
PI3Kb inhibition and was maintained for at least 24 hr. Increased
IRS1 and IGF1R expression and rebound in PI3K signaling in
the absence of IGF1 stimulation became evident 3, 6, and 5 hr
after PI3Kb inhibition, respectively, whereas increased IGF1R
phosphorylation in response to IGF1R was noted 6 hr afterward
(Figure 3F). Thus, transduction of the activated IGF1R signal is
suppressed in these tumors and enhanced after PI3Kb inhibition.
This enhancement likely plays a role in the induction of PI3Ka
signaling that occurs after PI3Kb inhibition. Induction of IRS1
plays amajor role in this process, and induction of IGF1R expres-
sion probably does as well; however, the kinetics in Figure 3F
show that this is a complex phenomenon and that other factors
are undoubtedly involved.
Combined Inhibition of PI3Ka and PI3Kb Enhances PI3K
Pathway Inhibition In Vivo
The optimal single agent murine dose of AZD8186 was deter-
mined to be 75 mg/kg BID, causing maximal inhibition of LNCaP
xenograft growth without weight loss at this or even higher doses
(100 mg/kg BID) (Figures S4A and S4B). This dose of AZD8186
had only minor effects on PI3Ka signaling in BT-474 xenografts
and no significant effects on tumor growth (Figures S4C and
S4D; Table S2). Mice bearing PTEN mutant LNCaP xenografts
were treated with a single dose of 75mg/kg of AZD8186, a single
dose of 25 mg/kg of BYL719, or the combination. Two hours af-
ter AZD8186 administration, reduced phosphorylation of Akt,
PRAS40, GSK3b, FOXO1/3, and S6K was observed and per-
sisted for 4 hr, but by 8 hr, Akt signaling had rebounded from
its nadir (Figure 4A). By 24 hr, phosphorylation of S6K and
PRAS40 rose to initial levels, whereas phosphorylation of Akt,
GSK3b, and FOXO1/3 had risen significantly but remained below
untreated levels (Figure 4A). Twenty-five mg/kg BYL719 (Fritsch
et al., 2014) had little effect on PI3K signaling in LNCaP but did
prevent the rebound observed with AZD8186 8 hr after drug
administration and substantially reduced the rebound at 24 hr
(Figure 4A). Similar results were obtained with these regimens
in PTEN mutant PC3 prostate cancer xenografts (Figure S4E).
We next examined whether the IGF1R pathway drives PI3Ka
reactivation in vivo in LNCaP xenografts. Seventy-five mg/kg
OSI-906 or 25 mg/kg BYL719 both significantly reduced the
rebound observed with AZD8186 (Figure S4F). These data sug-
gest that in these tumors feedback activation of PI3Ka following
PI3Kb inhibition in vivo is driven at least in part through IGF1R or
IR signaling.
Neither AZD8186 nor BYL719 had significant effects on
LNCaP, HCC70, or PC3 xenograft growth (Figures 4B, S4G,
and S4H; Tables S2). Combined treatment, results in significant
slowing, but not arrest, of the growth of LNCaP tumors (65% tu-
mor growth inhibition [TGI]) (Figure 4B; Table S2), tumor regres-
sion in HCC70 (143% TGI) (Figure S4G; Table S2) and significant
slowing of PC3 (84% TGI) (Figure S4H; Table S2). None of these
treatments had a significant effect on the weight of themice (Fig-
ures S4I and S4J).ancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc. 113
Figure 3. PI3Ka Activation Is IGF1R Dependent
(A) Expression and/or phosphorylation of several RTKs in LNCaP cells treated with 250 nM AZD8186 for the indicated times were examined by immunoblot
analysis.
(B) The phosphorylation of IGF1R (Y1131) in LNCaP cells treated with 250 nM AZD8186 for the indicated times was quantified by sandwich ELISA kit. The data
represent mean ± SD of triplicate samples.
(C) LNCaP cells were treated with 250 nM AZD8186 and collected at various time points. Immunoblotting analysis was performed as indicated. The change in the
expression of IRS1 was determined by densitometric analysis of the bands.
(D) LNCaP cells were treated with AZD8186 (250 nM), OSI-906 (2 mM), or the combination for the indicated times. Immunoblotting of lysates was used to examine
the effect on downstream signaling.
(legend continued on next page)
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PI3Kb Isoform Inhibitors in PTEN-Mutated TumorsThus, prolonged inhibition of PI3K signaling by combining
PI3Ka and PI3Kb inhibitors is associated with enhanced inhibi-
tion of tumor growth. A similar experiment was performed with
combined inhibition of PI3Kb and the IGF1R/IR inhibitor OSI-
906, but administration of either the latter alone or the combina-
tion was not tolerated due to more than 10% weight loss after
3 days of treatment (S.S. and N.R., unpublished data). These re-
sults suggest that prevention of rebound with the PI3Ka inhibitor
may be more feasible than with a dual IGF1R/IR kinase inhibitor.
Combined PI3Ka, PI3Kb, and Androgen Receptor
Inhibition Potently Inhibits PTEN Mutant Prostate
Tumors In Vivo
Durable inhibition of PI3K signaling was achieved with combined
inhibition of PI3Kb and PI3Ka but was not sufficient to arrest the
growth of thePTEN-mutated androgen receptor (AR)-dependent
LNCaP prostate cancer model. AR- and PI3K-driven signaling
are the two most commonly activated pathways in prostate can-
cer. We have recently shown that inhibition of either pathway re-
lieves feedback inhibition of the other (‘‘reciprocal feedback’’)
and that combined inhibition of both is required to adequately
inhibit tumor growth (Carver et al., 2011).
Inhibition of PI3Kb activates AR in LNCaP cells, as shown by
the induction of the expression of three AR target genes,
TMPRSS2, NKX3.1, and PSCA (Figure S5A). As shown previ-
ously (Carver et al., 2011), the potent AR inhibitor MDV3100
causes activation of Akt signaling (Figure S5B). To examine
whether activation of Akt after AR-inhibition is PI3K dependent,
we treated LNCaP cells with the AR inhibitor and added the
PI3Kb inhibitor or the PI3Ka inhibitor 6 hr later. AZD8186 addition
caused marked inhibition of Akt signaling. BYL719 also reduced
the induction of Akt phosphorylation byMDV3100, but to amuch
lesser extent (Figure S5C). Thus, it appears that induction of
PI3K signaling in response to AR inhibition is mediated by both
isoforms.
Addition of BYL719 to the combination of AZD8186 and
MDV3100 prevented the rebound in the phosphorylation of Akt
as well as the rebound induced by AZD8186 alone (Figure S5D).
The combination of MDV3100 and BYL719 had only a mild effect
on Akt signaling consistent with the dominant role of PI3Kb in
activating Akt (Figure S5D).
Inhibition of PI3Kb with AZD8186 induced the mRNA expres-
sion of the AR-target geneNKX3.1 2.7-fold after 24 hr (Figure 5A).
In contrast, the PI3Ka inhibitor BYL719 had no effect, consistent
with its lack of effect on PI3K signaling. However, BYL719
enhanced the induction of NKX3.1 observed with AZD8186
alone (4.4-fold above control; 1.7-fold above AZD8186). The
AR inhibitor MDV3100 reduced the expression of NKX3.1 (Fig-
ure 5A) and strongly blunted the induction of AR activity by the
PI3K inhibitors 8 hr after combined treatment and completely
suppressed the effect 24 hr after treatment (Figure 5A).
These results suggest that the antitumor effects of the PI3K in-
hibitors may be attenuated by their induction of AR signaling. In(E) LNCaP cells were treated with AZD8186, BYL719, OSI-906, or the combinatio
48 hr of treatment. Data are the mean percentage of Annexin V- positive cells ±
(F) LNCaP cells were treated with AZD8186 for various times. At the indicated
analysis was used to assay the effect on downstream signaling.
See also Figure S3.
Ctissue culture, combined inhibition of PI3Kb (AZD8186) and AR
(MDV3100) inhibited LNCaP proliferation more than either
drug alone (Figure 5B). Combining AZD8186 with MDV3100 or
BYL719 completely suppressed growth, and the triple combina-
tion was no better (Figure 5B). However, there were significant
differences in induction of cell death, as measured by Annexin
V staining (Figure 5C). Neither MDV3100 nor BYL719, alone
or in combination, induced apoptosis, whereas AZD8186
(250 nM) caused a 1.7-fold induction (Figure 5C). Combining
BYL719 with AZD8186 enhanced the effects of the latter, 2.4-
fold above control, 1.4-fold above AZD8186 alone (Figure 5C),
suggesting that the rebound in PI3Ka activity has a protective
effect on the tumor cell. Combining AR inhibition with PI3Kb
inhibition caused a similar increase. Combining both PI3K in-
hibitors with AR inhibition caused the greatest induction of
apoptosis—a 3.4-fold increase of Annexin V stained cells relative
to the control. The results imply that feedback reactivation of
either pathway in response to inhibition of the other serves to
limit apoptosis (Figure 5C).
We investigated the effects of suppressing both signaling
pathways in vivo. Mice bearing LNCaP tumors were castrated
and treated for 3 weekswith vehicle, individual drugs, or different
combinations. BYL719 and AZD8186 had only minor effects on
tumor growth when administered alone (36% and 40% TGI,
respectively) (Figure 5D). Combining both PI3K isoform inhibitors
had amuch greater effect (78%TGI), but the tumors continued to
grow slowly. Similar effects were noted when the AR inhibitor
MDV3100 was administered alone or in combination with
BYL719 (90% and 93% TGI). The combination of PI3Kb
(AZD8186) and AR (MDV3100) inhibitors was superior and
completely inhibited tumor growth (99% TGI) (Figure 5D; Table
S3). However, only the triple combination of AZD8186,
BYL719, and MDV3100 caused significant tumor regression,
which continued throughout the course of treatment (113%
TGI) (Figure 5D; Table S3). Images of representative tumors
from each treatment group reflect the effects depicted in the
growth curve (Figure 5E).
Combined inhibition of PI3K and AR was also studied in a
genetically engineeredmouse (GEM)model with prostate cancer
caused by conditional deletion of Pten (PB-Cre;Ptenlox/lox)
(Carver et al., 2011). In control mice, tumors grew slowly, with
a 12.5% increase in the size of established tumors over
30 days. Because of the slow growth of these models, we
considered a 30% decline in MRI tumor volume as a significant
antitumor effect.
We assessed the effects of administration of the PI3Kb inhib-
itor AZD8186 for 30 days and compared the results with three
combination therapies—AZD8186 and the PI3Ka inhibitor
BYL719, AZD8186 and the AR inhibitor MDV3100, and the triple
combination of AZD8186, BYL719, and MDV3100. After treat-
ment with 75 mg/kg AZD8186 for 30 days, tumor masses
comprised of intraductal carcinoma of the prostate had
increased in size by 2.86%, suggesting a modest inhibition ofns as indicated. Apoptotic cell death was quantified by Annexin V staining after
SD.
time cells were stimulated with IGF-1 (100 ng/ml) for 10 min. Immunoblotting
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Figure 4. Inhibition of the PI3K Pathway in Mice Bearing LNCaP Tumors
(A) Mice (n = 3mice per time point) bearing LNCaP tumors were randomized to receive vehicle, 75mg/kg AZD8186, 25mg/kg BYL719, or the combination of both
and were treated for the specified times. The tumors were analyzed by immunoblotting to assay downstream signaling.
(B) Mice bearing LNCaP tumors were randomized to receive vehicle, AZD8186 75 mg/kg twice per day, BYL719 25 mg/kg once per day, or the combination for
25 days. Tumor size was measured twice per week. The results are presented as the mean tumor volume ± SEM (n = 5 mice per group).
See also Figure S4 and Table S2.
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phosphorylation was still detectable by immunohistochemistry
at slightly reduced levels. In contrast, in mice treated with the
combination of PI3Ka and PI3Kb inhibitors, there was a marked
reduction in Akt phosphorylation (S473) (Figure 6B); however, in-
traductal prostatic carcinoma persisted and only slight inhibition
of tumor growth at 30 days compared with AZD8186 alone
(mean volume reduction of 6.1%) (Figures 6A and 6B).
In our experience, MDV3100 causes a 19.2% reduction in the
growth of this model in 30 days (Carver et al., 2011). Combined
inhibition of PI3Kb and AR led to a dramatic increase in antitumor
efficacy compared with either alone (mean tumor volume reduc-
tion of 45%), but despite PI3Kb inhibition, some persistence of
P-Akt was observed. Triple therapy (AZD8186, BYL719, and
MDV3100) was even more efficacious with a near complete
pathologic response (mean volume reduction of 84%), which
suggests that suppression of feedback reactivation of PI3Ka en-
hances antitumor activity (Figure 6). A reduction in nuclear AR
and Akt S473 phosphorylation occurs, and only microscopic ev-
idence of persistent focal prostatic intraepithelial neoplasia was
observed compared with AZD8186 alone (Figure 6B). Thus, in
both models, combined therapy with AR, PI3Ka, and PI3Kb in-
hibitors is required for maximal tumor regression. None of the116 Cancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc.treatments caused weight loss in the mice bearing LNCaP tu-
mors (Figure S5E), and nor were they associated with lethargy
or feeding abnormalities in the GEM model.
DISCUSSION
Tumors with mutant PIK3CA or PTEN have not been especially
sensitive to PI3K pathway inhibitors. Early studies focused on
the use of selective mTOR and Akt inhibitors, but PI3K signals
through other downstream targets in addition to Akt/mTOR.
Moreover, whereas PI3K, Akt, and mTOR inhibitors all relieve
feedback inhibition of RTKs, only PI3K inhibitors suppress
rather than reactivate PI3K. Inhibition of PI3K may therefore
be more effective therapeutically than inhibitors of downstream
elements of the pathway and recent preclinical work showing
that PI3K inhibitors have more potent antitumor activity than
Akt inhibitors supports this idea (Will et al., 2014; Ebi et al.,
2013). Early clinical experience with inhibitors of pan-class 1
PI3K was also disappointing, however (Martini et al., 2013).
This may have been due to a variety of factors, including the
off-target toxicity of nonselective drugs, the toxic effects of
PI3K inhibition, and the adaptation of the signaling network to
inhibition of the pathway.
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effective and potent inhibition of PI3K in tumors. Quite selective
PI3Ka, PI3Kb, and PI3Kd inhibitors have been developed and
have limited toxicity in preclinical models and early clinical trials
(Juric et al., 2012; Furman et al., 2014; Gopal et al., 2014). Such
drugs could be given at high enough doses to effectively sup-
press PI3K signaling in tumors dependent on particular PI3K iso-
forms. For instance, PI3Kd is selectively expressed in lymphoid
cells, and PI3Kd inhibitors have been shown to have impressive
clinical activity in a variety of B cell neoplasms (Furman et al.,
2014; Gopal et al., 2014). Similarly, PI3Ka inhibitors have signif-
icant activity in hormone-dependent breast cancers with mutant
PIK3CA (Juric et al., 2012).
We show here that PI3K signaling and tumor cell growth were
sensitive to selective inhibition of PI3Kb in PTEN-mutated tumor
cells but not in those driven by HER2 or mutant PIK3CA. PI3Kb
inhibition potently inhibited Akt/mTOR signaling in PTEN-
mutated tumors, whereas PI3Ka inhibition had no effect. How-
ever, inhibition of Akt/mTOR signaling by PI3Kb inhibition was
transient because inhibition of Akt/mTOR relieves feedback inhi-
bition of RTKs, thus reactivating PI3Ka.
Akt/mTOR signaling is driven by the dominant PI3K isoform in
the tumor, whether it is PI3Ka or PI3Kb. We and others have
shown that activation of Akt and mTOR causes feedback inhibi-
tion of RTK signaling by a complex and incompletely character-
ized set of mechanisms. Akt phosphorylates and inhibits FOXO
family transcription factors, thereby reducing the expression
of HER3, IR, and IGF1R—key physiologic activators of PI3K
signaling (Chandarlapaty et al., 2011; Muranen et al., 2012; Gar-
rett et al., 2013). Akt also activates mTOR, which then inhibits
RTK signaling in a complex manner that includes phosphoryla-
tion and degradation of IRS1 and IRS2, and phosphorylation
and stabilization of the PI3K inhibitory protein Grb10 (Yu et al.,
2011; Hsu et al., 2011; Simpson et al., 2001; Haruta et al.,
2000; O’Reilly et al., 2006). Thus, activation of Akt is expected
to inhibit both receptor signaling and expression, and inhibitors
of mTOR and Akt have been shown to relieve this feedback
and to reactivate PI3K signaling.
In the models we studied, PI3Kb inhibition variably induced
multiple receptors, IRS1, and IRS2 and the induction of PI3K
rebound was always reduced by an inhibitor of IGF1R/IR. Inhib-
itors of HER2 or HER1 affected rebound only in a fewmodels and
usually to a lesser degree (S.S. and N.R., unpublished data).
These data suggest that the dominant cause of rebound in the
tumors we studied in detail is relief of Akt/mTOR-dependent
feedback inhibition of IGF1R and IRS1 expression. It is likely
that in other cellular contexts other receptors are also involved
as the ligand environment and steady-state expression of recep-
tors will dictate the major mechanism of PI3Ka suppression in a
given tumor. This model has several implications. RTKs selec-
tively activate PI3Ka so it is clear why tumors in which these re-
ceptors are dysregulated are dependent on this isoform. Loss of
PTEN increases the half-life of PIP3 and results in a marked acti-
vation of Akt signaling. It is not clear why PTEN-mutated tumors
are selectively dependent on GPCR activation of PI3Kbwith little
or no input from RTK activated PI3Ka (Knight et al., 2006; Dbouk
and Backer, 2010; Fritsch et al., 2013). It is possible that PTEN
loss occurs preferentially in tumors derived from particular line-
ages in which signaling is dependent on GPCRs. Our findingsCsuggest a model in which PTEN loss leads to a hyperactivation
of Akt/mTOR that is expected to potently feedback inhibit
RTK-mediated activation of PI3Ka. Residual PI3Kb activity,
GPCR-dependent or not, is sufficient to maintain Akt activation
and suppression of RTK-dependent PI3Ka activation. This
model predicts that ligand activation of Akt will be suppressed
in such tumors. We did find that IGF did not activate Akt in
PTEN mutant LNCaP cells. However, pharmacologic inhibition
of PI3Kb is predicted to reduce feedback inhibition of receptor
signaling and cause a PI3Ka-dependent rebound in Akt/mTOR
signaling. In support of the model, we find that the ability of
IGF to activate Akt phosphorylation is restored as a function of
time after PI3Kb inhibition.
The model also suggests that receptor-mediated activation of
PI3Ka is more sensitive to Akt/mTOR feedback inhibition than
PI3Kb activation is. If so, PI3Kb inhibitors would cause reactiva-
tion of PI3Ka and a significant rebound in Akt phosphorylation
that would not reach baseline levels. We observe that this is
the case. In this issue of Cancer Cell, Costa et al. (2014) show
complementary results with a selective inhibitor of PI3Ka, which
inhibits Akt/mTOR signaling in tumors with RTK activation or
PI3K mutation, but not in those with PTEN inactivation. Inhibi-
tion of signaling by the PI3Ka inhibitor was also associated
with rebound, which in this case was sensitive to PI3Kb
inhibition.
Reactivation of PI3Ka prevents durable inhibition of signaling
by PI3Kb inhibitors and may limit their clinical efficacy.
AZD8186 effectively inhibits the growth of PTEN-mutated tumor
cells in vitro but induces only minimal apoptosis and has modest
antitumor activity in xenograft models. In contrast, combining
PI3Ka and PI3Kb inhibitors caused durable inhibition of PI3K
signaling, increased apoptosis, and enhanced antitumor activity.
In normal cells, both PI3Ka and PI3Kb contribute to the effects
of the pathway on metabolism and growth (Foukas et al., 2006;
Jia et al., 2008). This may be the basis for the lower toxicity of iso-
form-dependent inhibitors. This paper and that of Costa et al.
(2014) suggest that relief of feedback inhibition of the other iso-
forms may contribute as well. Combined therapy with PI3Ka and
PI3Kb inhibitors may cause greater ‘‘on-target’’ toxicity. We have
recently shown that intermittent administration of a PI3Ka prefer-
ential inhibitor has potent antitumor activity in vivo (Will et al.,
2014). Intermittent schedules may allow effective PI3K pathway
inhibition without inordinate toxicity.
It has become increasingly clear that activation of PI3K
signaling leads to feedback inhibition of androgen and estrogen
receptor signaling in prostate and breast cancer. InPTENmutant
prostate cancer, we have shown that AR activation causes feed-
back inhibition of PI3K signaling as well (Carver et al., 2011). This
reciprocal feedback inhibition of the two pathways limits the
therapeutic effects of inhibitors of either. PI3K pathway inhibition
has been almost completely ineffective in prostate cancer. In
fact, mTOR inhibitors have been shown to activate AR and
increase PSA in patients with advanced prostate cancer (H.I.S,
unpublished data). We show here that PI3Kb inhibition induces
the expression of AR-dependent gene expression and that
combined inhibition of PI3Kb and PI3Ka enhances this effect,
supporting the conclusion that suppression of PI3Ka rebound
significantly increases inhibition of pathway output. Given this
marked activation of AR-dependent gene expression, it is notancer Cell 27, 109–122, January 12, 2015 ª2015 Elsevier Inc. 117
Figure 5. Combined Inhibition of PI3Ka, PI3Kb, and AR Potently Inhibits LNCaP Tumors In Vitro and In Vivo
(A) LNCaP cell were treated as indicated and expression of NKX3.1 normalized to GAPDH was determined using quantitative RT-PCR (RT-PCR). Error bars
represent the SD of triplicate samples.
(B and C) LNCaP cell were treated as indicated, and cell growthwasmonitored with cell counter (B) (error bars represent the SD of triplicate samples) or apoptotic
cell death was quantified by Annexin V staining after 2 days of treatment (C) (data are the mean percentage of Annexin V-positive cells ± SD of two independent
experiments). Levene’s test for equality of variance was followed by an unpaired, two-tailed Student t test.
(legend continued on next page)
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modest antitumor effects in vivo in AR-dependent prostate can-
cer models. Similarly, AR inhibition causes tumor stasis, but not
regression in thesemodels. In contrast, the three-drug combina-
tion results in marked regression in both the GEM and xenograft
model.
The antitumor effects of selectivemTORandAkt inhibitorsmay
be limited because of their relief of feedback inhibition of PI3K.
Isoform-selective PI3K inhibitors have already shown significant
antitumor activity in tumors driven by PI3Ka or PI3Kd (Juric et al.,
2012; Furman et al., 2014; Gopal et al., 2014). PI3Kd is selectively
expressed in lymphoid cells, and PI3Kd inhibitors have been
shown to have marked benefit in a variety of B cell neoplasms
(Furman et al., 2014; Gopal et al., 2014). Similarly, PI3Ka inhibi-
tors such as BYL719 have significant single agent activity in
PI3Ka mutant breast cancers (Juric et al., 2012). In this paper
and in that of Costa et al. (2014), combined inhibition of PI3Kb
and PI3Ka was shown to durably suppress PI3K signaling in tu-
mors in which the pathway is activated by PTEN inactivation or
mutational or receptor activation of PI3Ka. We believe these
combinations represent promising therapeutic strategies for a
variety of PI3K dependent tumors. These depend on the use of
potent, selective inhibitors, and the suppression of pathways
that are reactivated in response to relief of feedback.
EXPERIMENTAL PROCEDURES
Cell Culture
Prostate cancer cell lines (LNCaP and VCaP) and the human breast cancer cell
lines (HCC70, ZR-75-1, BT-549, and BT-474) were obtained from the Amer-
ican Type Culture Collection. LNCaP, HCC70, ZR-75-1, BT-549, PC3,
LNCaP-AR, MEL-190, MEL-39, MEL-267, U-87MG, and IGROV1 were main-
tained in RPMI-1640 medium. BT-474, MDA-MB-468, and SKBR3 cells were
maintained in a 1:1 mixture of DME: F12 medium. VCaP cells were maintained
in DMEM medium. All media were supplemented with 4 mM glutamine, 100
units/ml each of penicillin and streptomycin, and 10% heat-inactivated fetal
bovine serum.
Targeted Pathway Inhibitors
The inhibitors that were used are described in Supplemental Experimental
Procedures.
In Vitro Kinase Assays
We utilized two different PI3K in vitro kinase assays in this work.
PI3Ka Kinase Activity Assay
To measure intracellular PI3Ka kinase activity, LNCaP cells were treated
with 250 nM AZD8186, and lysates were prepared. Kinase assays were per-
formed on PI3Ka immunoprecipitated in 250 mM ATP containing 10 mCi
[g32P] ATP with phosphatidylinositol as substrate. The product, phosphatidy-
linositol 3-phosphate, was resolved by thin-layer chromatography and
detected by autoradiography. This assay was described previously (Rodrik-
Outmezguine et al., 2011; She et al., 2005) and detailed in Supplemental
Experimental Procedures.
Determination of Isoform Selectivity of AZD8186
The inhibition of PI3Kb, PI3Ka, PI3Kg, and PI3Kd was evaluated in a Kinase
Glo based enzyme activity assay using the catalytic domain of each of(D) Castrated mice bearing LNCaP tumors were randomized to vehicle, AZD8186
kg) once per day, or the different combinations for 3 weeks. Tumor size was mea
SEM (n = 5 mice per group).
(E) Representative images of tumors following 3 weeks of treatment as in (D). Sca
1 cm.
See also Figure S5 and Table S3.
Cthe class I PI3K isoforms, as described in Supplemental Experimental
Procedures.
Immunoblot Analysis
Cell lysates were separated by SDS-PAGE as described in Supplemental
Experimental Procedures including a list of antibodies that were used.
siRNA Transfection
Accell siRNA was used according to the manufacturer’s protocol as described
in Supplemental Experimental Procedures.
RTK Arrays
Cells were washedwith cold PBS and lysed in NP-40 lysis buffer. Two hundred
fifty mg of cell lysateswere used to perform the Phospho-RTK arrays (R&DSys-
tems) following the manufacturer’s instructions.
Human IGF Signaling Array
Human cytokine arrays (Quantibody; RayBiotech) were used to determine
protein concentrations in cells; 250 mg of cell lysate were taken, and ana-
lyses were performed in accordance with the manufacturer’s instructions.
Imaging was performed using the Quantibody Array Testing Software
(RayBiotech).
IGF1Rb (Y1131) Sandwich ELISA Kit
PathScan Sandwich ELISA Kit was used to determine phosphorylation of
IGF1R (Y1131) in LNCaP cells treated with 250 nM AZD8186; 500 mg of cell
lysate was taken, and analyses were performed in accordance with the man-
ufacturer’s instructions (Cell Signaling).
Analysis of Cell Cycle and subG1
Cells were plated in six-well plates in triplicate and were treated with drug or
vehicle (DMSO) the following day for 5 days. Both adherent and floating cells
were harvested, and the cell nuclei were prepared as described previously
(She et al., 2008).
Analysis of Cell Growth
Cell growth was monitored by counting cells with a cell counter. Only viable
(adherent) cells were counted. Curves represent different treatments. Error
bars represent the SD of triplicate samples.
Analysis of Cell Apoptosis
Cell death was quantified by Annexin V (BioVision) staining, followed by flow
cytometric analyses, as described in Supplemental Experimental Procedures.
RT-PCR Analysis
Equal amounts of input RNAwere used in a real-time PCR as described in Sup-
plemental Experimental Procedures.
Mouse Models
Pten null GEM, BT-474 and LNCaP and BT-474 xenografts models were used
as described in Supplemental Experimental Procedures.
Animal studies were carried out under protocol 09-05-009 approved by the
MSKCC Institutional Animal Care and Use Committee. Institutional guidelines
for the proper, humane use of animals in research were followed.
MRI Animal Imaging
We used MRI to assess treatment response in our prostate GEM models as
described in Carver et al. (2011) and in Supplemental Experimental
Procedures.(75 mg/kg) twice per day, BYL719 (25 mg/kg) once per day, MDV3100 (30 mg/
sured twice per week. The results are presented as the mean tumor volume ±
le bar, determined using the diameter of the 10 cm plate as a scale, represents
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Figure 6. Triple Therapy of PI3Ka, PI3Kb, and AR Inhibitors Potently Inhibits Ptenlox/lox Prostate Tumors In Vivo
(A) Intact mice were treated with vehicle and castrated PB-Cre;Ptenlox/lox mice were treated with AZD8186 (75 mg/kg) twice per day alone, AZD8186 in com-
binationwith either BYL719 (25mg/kg) once per day orMDV3100 (30mg/kg) once per day, or the triple combination. Representativemagnetic resonance imaging
(legend continued on next page)
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Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.11.008.
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